|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Current assets: | |||||||||||||||||||
| Cash in escrow | |||||||||||||||||||
| Prepaid expense | |||||||||||||||||||
| Marketable securities held in trust account - current | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Noncurrent assets: | |||||||||||||||||||
| Marketable securities held in trust account | |||||||||||||||||||
| Total noncurrent assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| Liabilities and stockholders’ deficit | |||||||||||||||||||
| Current liabilities: | |||||||||||||||||||
| Accrued expenses and other liabilities | |||||||||||||||||||
| Due to related parties | |||||||||||||||||||
| Deferred underwriting commissions | |||||||||||||||||||
| Promissory note – Sponsor | |||||||||||||||||||
| Due to Sponsor | |||||||||||||||||||
| Redemption liability | |||||||||||||||||||
| Promissory notes and loan payable to Sponsor | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Noncurrent liabilities: | |||||||||||||||||||
| Deferred underwriting commissions | |||||||||||||||||||
| Total noncurrent liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Ordinary shares subject to possible redemption, 21,962 and 22,664 shares at redemption value of $37.10 and $31.68 per share at June 30, 2026 and December 31, 2025, respectively | |||||||||||||||||||
| Stockholders’ deficit: | |||||||||||||||||||
| Ordinary shares, par value $0.001, authorized 50,000,000 shares; 3,205,000 and 3,205,000 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively, excluding 21,962 and 22,664 shares subject to possible redemption | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total stockholders’ deficit | |||||||||||||||||||
| Total liabilities and stockholders’ deficit | |||||||||||||||||||
Loading...
